Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $0.79 Daily Weekly Monthly 20 Day Moving Average: 480,839 shares Shares Outstanding: 15.18 (millions) Market Capitalization: $11.95 (millions) Beta: 0.19 52 Week High: $2.48 52 Week Low: $0.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.29% 2.46% 12 Week -34.91% -40.87% Year To Date -54.47% -58.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@longeveron.com https://longeveron.com

• General Corporate Information    Officers Mohamed Wa'el Ahmed Hashad - Chief Executive Officer Lisa A. Locklear - Executive Vice President and Chief Financial Offic Joshua M. Hare - Director Rock Soffer - Director Richard Kender - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 15.18 Most Recent Split Date: 3.00 (0.10:1) Beta: 0.19 Market Capitalization: $11.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.94 Price/Cash Flow: - Price / Sales: 5.77 EPS Growth vs. Year Ago Period: 81.97% vs. Previous Quarter: 2.94% Sales Growth vs. Year Ago Period: -32.48% vs. Previous Quarter: -17.06% ROE 06/30/25 - -95.91 03/31/25 - -85.07 12/31/24 - -97.60 ROA 06/30/25 - -79.69 03/31/25 - -70.74 12/31/24 - -75.56 Current Ratio 06/30/25 - 3.43 03/31/25 - 5.61 12/31/24 - 7.60 Quick Ratio 06/30/25 - 3.43 03/31/25 - 5.61 12/31/24 - 7.60 Operating Margin 06/30/25 - -894.40 03/31/25 - -760.72 12/31/24 - -667.77 Net Margin 06/30/25 - -894.40 03/31/25 - -760.72 12/31/24 - -667.77 Pre-Tax Margin 06/30/25 - -894.40 03/31/25 - -760.72 12/31/24 - -667.77 Book Value 06/30/25 - 0.83 03/31/25 - 1.15 12/31/24 - 1.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 3.63

Powered by Zacks Investment Research ©